| DB ID | MyCo_5722 |
| Title | Interleukin-17A enhances host defense against cryptococcal lung infection through effects mediated by leukocyte recruitment, activation, and gamma interferon production |
| Year | 2013 |
| PMID | 24324191 |
| Fungal Diseases involved | Cryptococcal Lung infection |
| Associated Medical Condition | None |
| Genus | Cryptococcus |
| Species | neoformans |
| Organism | Cryptococcus neoformans |
| Ethical Statement | All studies involving mice were approved by the University Committee on Use and Care of Animals at the University of Michigan. |
| Site of Infection | Lungs |
| Opportunistic invasive | None |
| Sample type | Biopsy |
| Sample source | Extracted Lungs tissue |
| Host Group | Animal |
| Host Common name | Mice |
| Host Scientific name | Mus musculus |
| Biomarker Name | IL-17A |
| Biomarker Full Name | Interleukin-17A |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | Wild-type (C57BL/6J) mice obtained from the Jackson Laborato- ries (Bar Harbor, ME) were housed under pathogen-free conditions in enclosed filter-topped cages. |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Cryptococcus neoformans is a globally distributed pathogenic fungus acquired by the inhalational route. When host defenses are impaired, C. neoformans becomes a devastating op-portunistic pathogen. It is the leading cause of fatal mycosis in HIV-positive individuals (1 million new cases and 680,000 deaths per year) and the second most common fungal infection in patients with organ transplants. Yet for most infections in non-HIV patients, either the organism is fully cleared or it may persist at nonlethal levels, often resulting in destructive paren- chymal lung disease or immune-mediated airway damage and bronchiectasis. Thus, host defenses in immunocompetent humans are essential for clearance or containment of C. neoformans. |
| Technique | PCR |
| Analysis Method | qRT-PCR |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | qRT-PCR, Flow Cytometry Analysis |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
